oliver.stula@baselarea.swiss, Author at BaseLaunch

All

Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer

Allschwil, Switzerland – 10 June, 2025 – Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer. Dr. Barker joins Phialogics with…

oliver.stula@baselarea.swiss03.06.2025

Portfolio news

Hemastatx joins BaseLaunch portfolio

We’re excited to welcome Hemastatx to our portfolio. Hemastatx, a spin-off from KU Leuven, has emerged from stealth with funding from BaseLaunch, Gemma Frisius Fund and…

oliver.stula@baselarea.swiss27.05.2025

Portfolio news

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Basel, Switzerland – May 5, 2025 – metaLead Therapeutics AG (metaLead), a pioneering biotech company developing next-generation metal-binding therapies, announced today that it has secured…

oliver.stula@baselarea.swiss06.05.2025

All

Filing intellectual property (IP) on novel targets and epitopes

Filing intellectual property (IP) on novel targets and epitopes Building a strong IP portfolio is complex, especially when securing patents for novel targets and epitopes.…

oliver.stula@baselarea.swiss23.04.2025

Portfolio news

Ilonov joins BaseLaunch portfolio

Ilonov is harnessing groundbreaking discoveries to revolutionize treatment for metabolic disorders. By harvesting novel targets discovered from breakthrough research on the human muscle secretome, the…

oliver.stula@baselarea.swiss13.03.2025

oliver.stula@baselarea.swiss

Phialogics AG announces the appointment of Dr. Debra Barker as Chief Medical Officer

Hemastatx joins BaseLaunch portfolio

metaLead secures CHF 1 million investment to advance novel therapy for Wilson disease

Filing intellectual property (IP) on novel targets and epitopes

Ilonov joins BaseLaunch portfolio

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us